Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +55

Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?

AI-generated analysis

📈 Amgen reported Q2 2026 revenue of $10.1 billion, up 10% year over year, with non-GAAP EPS increasing 4% to $6.29.

💊 Key growth products advanced 26%, contributing significantly to the company's overall financial performance and cash generation.

⚠️ Mature franchises faced substantial biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34% in the quarter.

📢 Management raised its 2026 revenue guidance midpoint to $39.4 billion despite headwinds from legacy product erosion.

💰 The company generated $3.5 billion in Q2 free cash flow, providing substantial capital flexibility for strategic initiatives.

🔬 Wells Fargo raised its Amgen price target to $435 from $400, citing upside potential from HORIZON and olpasiran assets.

❤️ Repatha demonstrated reduced mortality risk by 20% in high-risk adults, with heart attack risk reductions emerging as early as six months.

📊 Hedge fund support increased slightly in Q2, with D.E. Shaw increasing its position by 625% to 1.29 million shares.

🚀 The company is tracking detailed Phase 3 data for olpasiran to clarify its cardiovascular positioning alongside Repatha's expanded benefits.

📉 Investors are advised to monitor how effectively new product launches offset the ongoing erosion from Prolia biosimilar competition.

Bullish Signals
  • Amgen reported Q2 2026 revenue of $10.1 billion, a 10% year-over-year increase driven by robust growth in key products which advanced 26%.
  • The company generated $3.5 billion in free cash flow during the quarter, providing substantial capital flexibility for future investments and strategic initiatives.
  • Management raised its full-year 2026 revenue guidance midpoint to $39.4 billion, signaling confidence in offsetting biosimilar erosion with new launches.
  • Wells Fargo raised its price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline assets like olpasiran.
  • Repatha recently showed a 20% reduction in death risk for high-risk adults, with heart attack risk reductions emerging as early as six months.
Risk Factors
  • Mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34% in Q2 2026.
  • Accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
Full Analysis
Amgen Inc. (NASDAQ: AMGN) reported solid Q2 2026 financial results with revenue reaching $10.1 billion, representing a 10% year-over-year increase. Non-GAAP EPS rose 4% to $6.29, driven by robust growth in key products which increased 26%. The company generated $3.5 billion in free cash flow during the quarter, providing substantial capital flexibility for future investments and shareholder returns. Despite positive momentum in its core portfolio, Amgen faces significant headwinds from biosimilar competition affecting its mature franchises. Revenue from Prolia declined 32% while XGEVA revenue fell 34%. To counter these challenges, management raised its full-year 2026 revenue guidance midpoint to $39.4 billion, signaling confidence in offsetting erosion with new product launches and pipeline assets like olpasiran. Analyst sentiment remains positive, with Wells Fargo raising its price target to $435 from $400 on September 4. The firm cited potential upside from the cardiovascular drug HORIZON and the expanded mortality benefits of Repatha, which recently showed a 20% reduction in death risk for high-risk adults. Hedge fund positioning also shows support, with major investors like D.E. Shaw increasing their stakes significantly. The article concludes that while Amgen presents a viable investment case supported by strong cash flow and pipeline potential, investors must monitor the effectiveness of new launches against biosimilar erosion. The company's ability to maintain margin expansion will depend on successfully navigating competitive pressures in legacy segments while capitalizing on growth opportunities in oncology and cardiovascular therapies.